Takeaways: Astellas’ Canadian real-world evidence strengthens the implementation case for CLDN18.2-targeted therapy by demonstrating a testing network across 13 validated centres, with a 6.1-day...
Browsing Tag: HER2-negative gastric cancer
Takeaways: Astellas’ Canadian real-world evidence strengthens the implementation case for CLDN18.2-targeted therapy by demonstrating a testing network across 13 validated centres, with a 6.1-day...